2,3-dihydro-1H-cyclopenta[b]quinoline derivatives as acetylcholinesterase inhibitors : synthesis, radiolabeling and biodistribution by Szymański, Paweł et al.
Int. J. Mol. Sci. 2012, 13, 10067-10090; doi:10.3390/ijms130810067 
 





2,3-Dihydro-1H-cyclopenta[b]quinoline Derivatives as 
Acetylcholinesterase Inhibitors—Synthesis, Radiolabeling  
and Biodistribution 
Paweł Szymański 1,*, Alice Lázničková 2, Milan Lázniček 2, Marek Bajda 3, Barbara Malawska 3, 
Magdalena Markowicz 1 and Elżbieta Mikiciuk-Olasik 1  
1 Department of Pharmaceutical Chemistry and Drug Analyses, Medical University,  
ul. Muszyńskiego 1, Lodz 90-151, Poland; E-Mails: magdalena.markowicz@umed.lodz.pl (M.M.); 
elzbieta.mikiciuk-olasik@umed.lodz.pl (E.M.-O.) 
2 Faculty of Pharmacy in Hradec Kralove, Charles University in Prague, Heyrovskeho 1203,  
Hradec Kralove CZ-50005, Czech Republic; E-Mails: alice.laznickova@faf.cuni.cz (A.L.); 
milan.laznicek@faf.cuni.cz (M.L.) 
3 Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University 
Medical College, Medyczna 9, Krakow 30-688, Poland; E-Mails: marek.bajda@uj.edu.pl (M.B.); 
barbara.malawska@uj.edu.pl (B.M.) 
* Author to whom correspondence should be addressed; E-Mail: pawel.szymanski@umed.lodz.pl; 
Tel./Fax: +48-42-677-9250. 
Received: 14 June 2012; in revised form: 7 July 2012 / Accepted: 6 August 2012 /  
Published: 13 August 2012 
 
Abstract: In the present study we describe the synthesis and biological assessment of new 
tacrine analogs in the course of inhibition of acetylcholinesterase. The obtained molecules  
were synthesized in a condensation reaction between activated 6-BOC-hydrazinopyridine-
3-carboxylic acid and 8-aminoalkyl derivatives of 2,3-dihydro-1H-cyclopenta[b]quinoline. 
Activities of the newly synthesized compounds were estimated by means of Ellman’s 
method. Compound 6h (IC50 = 3.65 nM) was found to be most active. All obtained novel 
compounds present comparable activity to that of tacrine towards acetylcholinesterase 
(AChE) and, simultaneously, lower activity towards butyrylcholinesterase (BChE). Apart 
from 6a, all synthesized compounds are characterized by a higher affinity for AChE and a 
lower affinity for BChE in comparison with tacrine. Among all obtained molecules, 
compound 6h presented the highest selectivity towards inhibition of acetylcholinesterase. 
Molecular modeling showed that all compounds demonstrated a similar binding mode with 
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AChE and interacted with catalytic and peripheral sites of AChE. Also, a biodistribution 
study of compound 6a radiolabeled with 99mTc was performed.  




Alzheimer’s disease (AD), the most common form of dementia with an incidence that is highly age 
dependent, is a degenerative disease of the central nervous system characterized by a noticeable 
cognitive decline. The most characteristic symptoms of AD are memory loss, deficit in learning ability, 
and a reduced ability to perform the basic activities of daily living. With the ageing of the world 
population, the prevalence, cost, and potential societal effects of AD will increase with certainty.  
Several theories explaining the mechanism of AD development have been proposed by scientists 
over the past decades. Loss of cholinergic function, known as cholinergic hypothesis, amyloid cascade 
(amyloid hypothesis), oxidative stress, decrease of steroid hormone concentration, and an 
inflammatory process are most often mentioned [1]. The widely accepted cholinergic hypothesis has 
been verified repeatedly. 
The most characteristic abnormality associated with AD is a decrease in central cholinergic 
neurotransmission, a consequence of decreased activity of choline acetyltransferase (ChAT), an 
enzyme that synthesizes acetylcholine (ACh) [2,3]. Acetylcholine, an ester of choline and acetic acid, 
acts in both the peripheral nervous system and central nervous system. The second enzyme which 
influences the level of ACh is acetylcholinesterase (AChE). In its natural state, it is a monomer with a 
molecular weight of approximately 60 kDa; often, however, it forms aggregates which continue to 
produce catalytic activity. The enzyme monomer is an α/β protein that contains 537 amino acids.  
It consists of a 12-stranded mixed beta sheet surrounded by 14 alpha helices [4].  
Recent scientific reports suggest that AChE also plays a non-cholinergic role in the development of 
AD [5,6] by working as a chaperone molecule, accelerating the Aβ peptide deposition, and the 
aggregation of Aβ into insoluble fibrils [7,8]. 
One of the most popular therapeutic strategies in the treatment of AD is the control of cholinergic 
neurotransmission by slowing down the decline of neuronal degeneration or increasing cholinergic 
transmission [9]. Acetylcholinesterase inhibitors (AChEIs), which increase the synaptic amount of 
ACh by preventing its degradation, constitute the best-developed and widely approved class of AD 
drugs [10–13] and are used for mild-to-moderate stages of the disease. Results of clinical trials and 
imaging suggest that this group of drugs may lead also to a reduction in amyloid precursor protein 
(APP) formation [11]. Tacrine (1,2,3,4-tetrahydro-9-acridinamine-monohydrochloride) was the first 
drug approved by the United States Food and Drug Administration in 1993 for the palliative treatment 
of AD. It is a centrally active non-competitive reversible acetylcholinesterase inhibitor. However, its 
use is limited by a significant incidence of hepatotoxicity, cardiovascular system impairment, and mild 
cognitive benefits, while not altering the course of the disease [14].  
Int. J. Mol. Sci. 2012, 13 10069 
 
 
Nevertheless, the search for new candidates–tacrine analogues is still of interest to scientists 
involved in AD research [15,16]. For example, 6-fluorotacrin-1-ol and 6-chlorotacrin-1-ol were found 
to be more potent than tacrine [17]. In the last decade, analogues containing two tacrine moieties 
linked by an alkylene chain were synthesized. It was reported that these dimeric molecules of tacrine 
were characterized by a stronger potency and a higher selectivity towards AChE [18,19]. It was proven 
that bis-(7)-tacrine had several modes of action, such as inhibition of AChE, N-Methyl-D-aspartate 
(NMDA) receptors, and nitric oxide synthase signaling. Furthermore, several homodimeric tacrine-based 
AChE inhibitors were synthesized. Their increased inhibitory potency was believed to be derived from 
the simultaneous binding of the units to the active and peripheral anionic sites of AChE [19]. One  
of these novel compounds, heptylene-linked bis-tacrine, was found to be 150-fold more active  
against rat AChE than tacrine and 250-fold more selective for acetylcholinesterase (AChE) than for 
butyrylcholinesterase (BChE) [20].  
Second generation AChEIs (donepezil, rivastigmine and galantamine) demonstrate greater efficacy 
in AD treatment. Furthermore, when compared to tacrine, these drugs have fewer side effects and 
longer half-lives [6]. Therefore, synthesis of the analogues of the approved drugs: donepezil, rivastigmine, 
and galantamine is still of interest for many research groups [21,22]. 
Because of the complex pathophysiology of AD, involving numerous pathways, development of a 
satisfactory therapy is problematic. The key therapeutic targets are diffuse loss of neurons, reduced 
levels of the neurotransmitter acetylcholine (ACh), deposits of β-amyloid (Aβ) plaques, and neurofibrillary 
tangles [23]. For example, Tomassoli et al. reported that new 4-hydroxy-2-oxo-1,2-dihydroquinoline-
3-carboxamides, 4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carbohydrazide, and hexahydropyrimido 
[5,4-c]quinoline-2,5-diones were characterized by moderate activity towards AChE/BuChE inhibition; 
none of the synthesized compounds, however, showed higher inhibitory activity than tacrine [24]. 
Another scientific team investigated the potential activity of substituted 2-aminopyridine-3-carbonitriles 
towards AChE and BChE inhibition. Biological studies showed that some of these molecules were 
good AChE inhibitors, in the nanomolar range, and quite selective with regards to the inhibition of 
BChE [25]. 
The purpose of this study was to synthesize new derivatives of 2,3-dihydro-1H-cyclopenta 
[b]quinoline and nicotinic acid and to determine their activity towards inhibition of AChE and BChE. 
Furthermore, the selectivity of synthesized compounds was determined. This is significant for further 
phases of our study related to complexation of radioactive isotopes because during the design of novel 
potential radiopharmaceuticals selectivity and capability of binding with specified biological targets 
are more important than activity. Molecular modeling studies for synthesized compounds were also 
performed in order to elucidate the interactions between the enzymes and synthesized compounds. 
Furthermore, one of the synthesized molecules (compound 6a) was labeled with 99mTc and a 
biodistribution study of radioactivity was conducted following intravenous administration of 99mTc-6a 
to rats in order to estimate its potential as diagnostic marker in AD. 
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2. Results and Discussion 
2.1. Chemistry 
The first step of the synthesis was the preparation of 6-BOC-hydrazinopyridine-3-carboxylic acid 
(2). The substrate for this synthesis was 6-chloronicotinic acid. This compound reacted with hydrazine 
to give 6-hydrazinenicotinic acid (1). Subsequently, it was treated with di-tert-butyl dicarbonate and 
triethylamine in the presence of dimethylformamide (Scheme 1).  
Scheme 1. Synthesis of 6-BOC-hydrazinopyridine-3-carboxylic acid. Reagents:  





















These syntheses were described earlier by Abrams and co-workers [26]. 8-chloro-2,3-dihydro-1H-
cyclopenta[b]quinoline (3) was prepared according to a procedure mentioned in a previous paper [17]. 
This reaction involved cyclization of anthranilic acid with cyclopentanone in POCl3. Subsequently, the 
obtained compound (3) was coupled with the appropriate alkyldiamine (number of carbon atoms 
ranging from 2 to 9) and giving 8-amino-2,3-dihydro-1H-cyclopenta[b]quinolines (Scheme 2) [27–31]. 
Scheme 2. Synthesis of compounds (3), 4a–4h. Reagents: (a) cyclopentanone, POCl3, 
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Novel compounds were obtained via the synthesis between 6-(N'-tertbutoxycarbonylhydrazino)-
nicotinic acid (2), previously activated by 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT), and  
N-methylmorpholine in solvent and reacted with compounds 4a–4h. The best results (75% yield) in 
this reaction were achieved with drop by drop addition of N-methylmorpholine to the solution in 
tetrahydrofuran at −5 °C. Monitoring the reaction by TLC showed that the reaction of activation of the 
carboxylic group was usually completed within 1–4 h; subsequently, a mixture of the appropriate  
reactant 4a–4h in the respective solvent was added at −5 °C. The last step of the synthesis involved 
conversion of the obtained compounds 5a–5h into hydrochlorides 6a–6h (Scheme 3) in the presence of 
hydrochloric acid with recrystallization from HCl in ether. In this step, the BOC group split off and the 
new compound precipitated. 
Scheme 3. Synthesis of compounds 5a–5h and 6a–6h. Reagents: (a) Reactant 2, 2-chloro-





4e, 5e, 6e: n=6
4f, 5f, 6f:    n=7
4g, 5g, 6g: n=8
4h, 5h, 6h: n=9
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4b, 5b, 6b: n=3
4c, 5c, 6c: n=4




















2.2. Pharmacological Evaluation 
2.2.1. Studies of AChE/BChE Inhibition  
The activity of the synthesized compounds towards inhibition of both enzymes (AChE and BChE) 
was estimated by Ellman’s spectrophotometric method [32–34]. Table 1 presents IC50 values of the 
newly obtained compounds with respect to AChE and BChE inhibition. Among these molecules, the 
most active towards inhibition of AChE appears to be molecule 6h (IC50 = 3.65 nM). Compound 6g 
(IC50 = 5.17 nM) exhibits a similar value of IC50 to tacrine. Obtained data shows that all synthesized 
molecules were characterized by lower BChE inhibitory activity in comparison with tacrine. Table 1 
also lists values of relative inhibitory effects towards acetylcholinesterase (ratio IC50 BChE/AChE) and 
butyrylcholinesterase (ratio IC50 AChE/BChE). The most active molecule, compound 6h, was more 
selective for AChE than tacrine. Derivative 6g, with similar activity with regard to tacrine, was 
characterized by a higher selectivity for AChE in comparison with tacrine. All acquired compounds 
possessed lower affinity for BChE than tacrine; among all synthesized compounds, compound 6a 
presented the highest activity for BChE. These findings are significant in view of the pathological 
processes involved in this type of neurodegenerative disease [35]. 
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Table 1. IC50 values for activities towards acetylcholinesterase (AChE) and 
butyrylcholinesterase (BChE).  
Compound AChE IC50, (nM)  
± SEM a 
BChE IC50, (nM)  
± SEM b 




6a 31.50 ± 1.9 164.00 ± 1.6 5.21 0.19 
6b 19.30 ± 1.1 197.00 ± 3.4 10.21 0.10 
6c 22.40 ± 1.7 2650.00 ± 9.5 118.30 0.01 
6d 7.84 ± 2.2 4240.00 ± 2.2 540.82 0.00 
6e 41.60 ± 1.0 16600.00 ± 17.5 399.04 0.00 
6f 17.60 ± 0.8 22700.00 ± 20.6 1289.77 0.00 
6g 5.17 ± 1.4 19600.00 ± 16.4 3791.10 0.00 
6h 3.65 ± 0.5 17100.00 ± 21.3 4684.93 0.00 
tacrine 5.46 ± 1.0 2.44 ± 0.6 0.45 2.24 
a Inhibitor concentration (means ± SEM of three experiments) for 50% inactivation of AChE;  
b Inhibitor concentration (means ± SEM of three experiments) for 50% inactivation of BChE;  
c Selectivity for AChE is defined as IC50(BChE)/IC50(AChE); d Selectivity for BChE is defined as 
IC50(AChE)/IC50(BChE). 
2.2.2. Studies of Molecular Modeling 
A novel series of compounds was docked to acetyl- and butyrylcholinesterase to show the possible 
interactions between inhibitors and enzymes. All ligands demonstrated a similar binding mode with 
AChE. They were extended along the active gorge and interacted with catalytic and peripheral sites. 
The most active molecule (compound 6h) and its binding mode are presented in Figure 1. The 
fragment of the tacrine analogue with a cyclopentane ring created a characteristic sandwich due to π−π 
stacking with Trp84 and Phe330. The linker was located in the middle of the gorge, where it formed 
hydrophobic interactions with aromatic rings of Tyr121 and Tyr334. The nicotinamide moiety, in 
particular the amide bond, was located between two aromatic residues of the peripheral anionic  
site—Tyr70 and Trp279. Hydrazine interacted by H-bonding with the carbonyl group of the Asp276 
backbone which was why the pyridine ring was shifted and was not able to create classical π−π 
stacking; it was engaged in some hydrophobic interactions. 
Figure 1. Binding mode of compound 6h with acetylcholinesterase.  
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In the case of butyrylcholinesterase, the binding mode of the cyclopentaquinoline moiety was 
similar. The small differences concerned the location of the hydrazinenicotinic fragment in the reduced 
peripheral anionic site of BChE. The binding mode of the most potent butyrylcholinesterase inhibitor 
6a is shown in Figure 2. A fragment of the tacrine analogue created π–π stacking with Trp82 and  
CH–π interactions with Trp430. The carbonyl group of the inhibitor amide bond formed H-bonding 
with OH Thr120 and the hydrazine moiety with the C=O of the Ile69 backbone. 
Figure 2. Binding mode of compound 6a with butyrylcholinesterase. 
 
2.2.3. Radiolabeling with 99mTc and Biodistribution Studies in Rats 
Compound 6a was designed for radiolabeling. Also, spectrophotometric experiments were 
performed to determine its stability in water (Figure 3). 
Figure 3. UV spectra of compound 6a in aqueous solution at different times of incubation  
(0 to 4 h, measured every 15 min). 



















Int. J. Mol. Sci. 2012, 13 10074 
 
 
Taking into consideration all synthesized compounds, compound 6a is characterized by the highest 
selectivity towards BChE. Assessment of the level of this enzyme is very important as it is different in 
various stages of Alzheimer’s disease. Quality control of 99mTc-labeled HYNIC-compounds with 
tricine as coligand with HPLC confirmed the purity of the product, which was found to be without 
unbound technetium (pertechnetate or hydrolyzed form, which would have appeared after a short elution 
time) [36]. Figure 4 presents radiochromatograms of complexes formed by technetium-99m with tricine 
and HYNIC. 
Figure 4. Radiochromatograms of complexes formed by technetium-99m with tricine and 
hydrazine nicotinate (HYNIC). (a) Compound 6a; (b) Compound 6a after 24 h. 
 
Table 2 presents the tissue distribution of radioactivity after intravenous administration of 99mTc-6a 
to rats. Collectively, compound 6a exhibited relatively rapid blood radioactivity clearance; a large 
percentage of 99mTc-radioactivity was located in the liver, but also partly in the kidney, lung, and the 
gastrointestinal tract. Whereas the liver radioactivity uptake persisted for a long time for 99mTc-6a 
(Table 2), radioactivity found in the kidney and the gastrointestinal tract is more likely connected with 
elimination of the parent compounds and/or their metabolites from the body. Radioactivity 
concentrations in the brain were very low; probably, as a result of the hydrophilicity of radiolabelled 
compounds (the effect of technetium and co-ligands attached to the 2,3-dihydro-1H-cyclopenta 
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[b]quinoline analogues), which are unable to cross the blood-brain barrier. This behavior is 
disadvantageous for the intended use of the agents for diagnosis of Alzheimer’s disease.  
Table 2. Distribution of radioactivity in selected organs and systems of rats after 
intravenous administration of 99mTc-6a. 
99mTc-6a (% Dose/g) 
Organs 5 min 60 min 120 min 24 h 
Blood 0.850 ± 0.108 0.114 ± 0.015 0.091 ± 0.017 0.033 ± 0.004 
Plasma 0.921 ± 0.124 0.183 ± 0.024 0.150 ± 0.027 0.052 ± 0.003 
Pancreas 0.551 ± 0.109 0.117 ± 0.019 0.092 ± 0.015 0.067 ± 0.006 
Liver 5.752 ± 0.742 5.160 ± 0.586 5.630 ± 0.508 5.095 ± 0.478 
Adrenals 1.186 ± 0.231 0.900 ± 0.102 0.890 ± 0.040 0.793 ± 0.137 
Kidney 3.838 ± 0.264 1.556 ± 0.148 1.332 ± 0.209 1.026 ± 0.130 
Lung 3.497 ± 0.239 2.010 ± 0.323 1.824 ± 0.438 1.354 ± 0.066 
Heart 0.779 ± 0.078 0.241 ± 0.013 0.204 ± 0.025 0.147 ± 0.009 
Spleen 0.999 ± 0.218 1.840 ± 0.618 2.172 ± 0.391 2.631 ± 0.199 
Stomach 0.206 ± 0.044 0.469 ± 0.438 0.311 ± 0.153 0.571 ± 0.389 
Intestine 0.977 ± 0.313 4.242 ± 0.113 3.661 ± 1.491 0.196 ± 0.055 
Colon 0.108 ± 0.031 0.044 ± 0.003 1.566 ± 1.539 1.809 ± 0.976 
Testes 0.054 ± 0.004 0.033 ± 0.001 0.030 ± 0.005 0.022 ± 0.003 
Skin 0.290 ± 0.039 0.196 ± 0.017 0.169 ± 0.029 0.100 ± 0.010 
Muscle 0.157 ± 0.004 0.056 ± 0.007 0.048 ± 0.006 0.037 ± 0.005 
Thyroid 0.551 ± 0.040 0.225 ± 0.021 0.189 ± 0.009 0.124 ± 0.037 
Brain 0.049 ± 0.003 0.013 ± 0.001 0.014 ± 0.003 0.007 ± 0.001 
Fat 0.305 ± 0.060 0.120 ± 0.019 0.105 ± 0.017 0.070 ± 0.017 
Femur 0.330 ± 0.036 0.202 ± 0.015 0.218 ± 0.031 0.232 ± 0.037 
3. Experimental Section  
3.1. Chemistry 
During conducted syntheses dry organic solutions were used. This was achieved by employing 
anhydrous Na2SO4. Solvents were removed with a rotary evaporator. Melting points were determined 
by using an Electrothermal apparatus with open capillaries and were uncorrected. For monitoring of 
conducted reactions, TLC with 25 DC-Alufolien Kieselgel 60F254 (Merck) was used; detection was 
carried out with a UV Lamp (254 nm). Column chromatography was executed using silica gel 60 
(200–400 mesh, Merck). For determining IR spectra, Mattson Infinity Series FT-IR spectrophotometer 
was used. IR spectra were recorded in KBr. 1H NMR spectra were recorded with Varian Mercury  
300 MHz spectrometer, with tetramethylsilane as an internal standard. Mass spectra were performed 
by the Centre of Molecular and Macromolecular Studies in Lodz (Polish Academy of Sciences). 
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3.1.1. 6-Hydrazinopyridine-3-carboxylic Acid (1) 
6-Chloronicotinic acid (8.0 g, 50.77 mmol) was dissolved in 80% hydrazine hydrate (35 mL,  
930.0 mmol) and placed in a 100 °C oil bath for 4 h. The homogeneous reaction mixture was cooled to 
room temperature and concentrated to dryness to give a white solid. The solid was dissolved in water 
and on acidification to pH 5.5 with concentrated hydrochloric acid, a precipitate was formed. The 
precipitate was isolated by filtration; the solid was washed with 95% ethanol and ether, and dried in 
vacuum. Compound 1: yield 85%; mp 292–293 °C; 1H NMR (DMSO) (δ ppm.): 8.5 (1H, s, COOH), 
8.3 (1H, s, CHN), 7.8 (1H, d, J = 2.4 Hz CCHC), 6.7 (1H, d, J = 8.8 Hz, CCHC), 3.2 (1H, s, CNH), 2.5 
(2H, s, NH2); IR (KBr) ν (cm−1): 1333.0, 3080.1, 3308.2; MS (FAB) m/z (M + 1) 154.1; Elemental 
Analysis: Calc. for C6H7N3O2: C 47.06, H 4.61, N 27.44 Found: C 46.79 H 4.86 N 27.14. 
3.1.2. 6-BOC-hydrazinopyridine-3-carboxylic Acid (2) 
To a solution of 1 (1.4 g, 9.8 mmol) and triethylamine (1.2 mL, 11.8 mmol) in DMF (10 mL) was 
added di-tert-butyl dicarbonate (2.13 g, 9.8 mmol). The reaction mixture became homogeneous over  
1 h and stirring was continued for 16 h at room temperature. The reaction mixture was concentrated to 
dryness under reduced pressure to give a brown solid. Recrystallization from ethyl acetate gave the 
desired product 2 as a white solid. Compound 2: yield 66%; mp 282–285 °C; 1H NMR (DMSO)  
(δ ppm.): 12.5 (1H, s, COOH), 8.9 (1H, d, J = 2.4 Hz NHC), 8.6 (1H, s, CHN), 7.9 (1H, d, J = 8.8 Hz, 
CCHC), 6.5 (1H, d, J = 8.8 Hz CCHC), 3.3 (1H, s, CNH), 1.9 (9H, s, BOC); IR (KBr) ν (cm−1): 
1608.8, 1706.4, 3253.7; MS (FAB) m/z (M + 1) 254.2, 198.0; Elemental Analysis: Calc. for C11H15N3O4: 
C 52.17, H 5.97, N 16.59 Found: C 51.35, H 6.07, N 16.29. 
3.1.3. 9-Chloro-2,3-dihydro-1H-cyclopenta[b]quinoline (3) 
To a mixture of anthranilic acid (7.4 g, 53.9 mmol) and cyclopentanone (1.64 mL, 53.9 mmol) was 
carefully added 30 mL of POCl3 in an ice bath. The mixture was heated under reflux for 2 h, then 
cooled to room temperature, and concentrated under reduced pressure to give a slurry. The residue was 
diluted with ethyl acetate (50 mL), neutralized with aqueous K2CO3 (30 mL), and washed with brine  
(2 × 20 mL). The organic layer was dried over MgSO4 and concentrated to dryness under reduced 
pressure to give a brown solid. Recrystallization from acetone gave the desired product 1 as a yellow 
solid. Compound 1: yield 54%; mp 85–87 °C; 1H NMR (CDCl3) (δ ppm.): 8.1 (1H, d, J = 8.3 Hz, 
ArH), 7.9 (1H, d, J = 8.5 Hz, ArH), 7.6 (1H, t, J = 6.9 Hz, ArH), 7.4 (1H, t, J = 6.9 Hz, ArH), 3.0 (2H, 
d, J = 5.9 Hz, CH2), 2.9 (2H, d, J = 5.0 Hz, CH2), 1.8 (2H, t, J = 6.9 CH2); IR (KBr) ν (cm−1): 766.2, 
1607.2, 2955.1, 2920.7, 3417.8.  
3.1.4. N'-(2,3-Dihydro-1H-cyclopenta[b]quinolin-9-yl)ethane-1,2-diamine (4a) 
A mixture of 3 (0.71 g, 3.5 mmol), 1,2-diaminoethane (0.47 mL, 7 mmol), phenol (1.5 g), and NaI 
(0.07 g) was carefully heated at 180 °C for 2 h and then cooled to room temperature. The mixture was 
diluted with ethyl acetate (50 mL) and made basic with 10% KOH solution (30 mL). The organic layer 
was washed with water (20 mL) and brine (2 × 20 mL), and then dried over MgSO4 and concentrated 
under reduced pressure. The resulting residue was purified with silica gel chromatography (CH2Cl2: 
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CH3OH:NH3 = 10:4.6:0.5) to afford 4a as an oil. Compound 4a: yield 64%; 1H NMR (CDCl3)  
(δ ppm.): 7.8 (1H, d, J = 8.3 Hz, ArH), 7.7 (1H, d, J = 8.3 Hz, ArH), 7.5 (1H, t, J = 6.9 Hz, ArH), 7.3 
(1H, t, J = 8.1 Hz, ArH), 5.4 (1H, s, NH), 3.6 (2H, d, J = 5.4 Hz, NHCH2), 3.1 (2H, t, J = 7.3 Hz 
CH2NH2), 2.8–3.0 (4H, m, CH2), 2.6 (2H, p, J = 7.5, 7.5 Hz CH2), 1.6 (2H, s, NH2), IR (KBr) ν (cm−1): 
1570.4, 2856.4, 2924.5, 2950.0, 3355.7; MS (FAB) m/z (M + 1) 228.1, 197.0, 185.0; MS-HR (FAB) 
Calc. for C14H17N3: 227.1422 Found: 227.14195. 
3.1.5. N'-(2,3-Dihydro-1H-cyclopenta[b]quinolin-9-yl)propane-1,3-diamine (4b) 
A mixture of 3 (0.71 g, 3.5 mmol), 1,3-diaminopropane (0.58 mL, 7 mmol), phenol (1.5 g), and NaI 
(0.07 g) was combined as above to afford 4b as an oil. Compound 4b: yield 72%; 1H NMR (CD3OD) 
(δ ppm.): 8.0 (1H, d, J = 7.6 Hz, ArH), 7.7 (1H, d, J = 7.6 Hz, ArH), 7.6 (1H, t, J = 7.1 Hz, ArH), 7.4 
(1H, t, J = 6.8 Hz, ArH), 3.7 (2H, t, J = 7.1 Hz, NHCH2), 3.3 (2H, t, J = 7.1 CH2NH2), 3.0 (2H, t,  
J = 7.1 Hz, CH2), 2.8 (2H, t, J = 7.1 Hz CH2), 2.1 (2H, p, J = 7.6, 7.8 Hz CH2), 1.9 (2H, p, J = 7.1, 7.1 Hz, 
CH2); IR (film) ν (cm−1): 1568.8, 2870.4, 2951.9, 3348.7; MS (FAB) m/z (M + 1) 242.2, 197.0, 185.0; 
MS-HR (FAB) Calc. for C15H19 N3: 241.1579 Found: 241.15789. 
3.1.6. N'-(2,3-Dihydro-1H-cyclopenta[b]quinolin-9-yl)butane-1,4-diamine (4c) 
A mixture of 3 (0.71 g, 3.5 mmol), 1,6-diaminohexane (0.81 g, 7 mmol), phenol (1.5 g), and NaI 
(0.07 g) was combined as above to afford 4c as an oil. Compound 4c: yield 52%; 1H NMR (CD3OD)  
(δ ppm.): 8.0 (1H, d, J = 7.6 Hz, ArH), 7.7 (1H, d, J = 7.3 Hz, ArH), 7.5 (1H, t, J = 6.8 Hz, ArH), 7.4 
(1H, t, J = 8.3 Hz, ArH), 3.6 (2H, t, J = 6.3 Hz, NHCH2), 3.2 (2H, t, J = 7.1 CH2NH2), 2.9 (2H, t,  
J = 7.8 Hz, CH2), 2.7 (2H, t, J = 7.1 Hz CH2), 2.1 (2H, p, J = 7.6, 7.6 Hz CH2), 1.6–1.8 (4H, m, CH2); 
IR (film) ν (cm−1): 1566.8, 2865.0, 2934.1, 3304.1; MS (FAB) m/z (M + 1) 256.2, 197.0, 185.0;  
MS-HR (FAB) Calc. for C16H21N3: 255.1735 Found: 255.17328. 
3.1.7. N'-(2,3-Dihydro-1H-cyclopenta[b]quinolin-9-yl)penthane-1,5-diamine (4d) 
A mixture of 3 (0.71 g, 3.5 mmol), 1,5-diaminopentane (0.82 mL, 7 mmol), phenol (1.5 g), and NaI 
(0.07 g) was combined as above to afford 4d as an oil. Compound 4d: yield 75%; 1H NMR (CDCl3)  
(δ ppm.): 7.8 (1H, d, J = 7.3 Hz, ArH), 7.6 (1H, d, J = 7.5 Hz, ArH), 7.5 (1H, t, J = 6.9 Hz, ArH), 7.3 
(1H, t, J = 6.9 Hz, ArH), 4.6 (1H, s, NH), 3.5 (2H, m, NHCH2), 3.1 (2H, t, J = 6.9 Hz, CH2), 3.0 (2H, t, 
J = 7.7 Hz, CH2NH2), 2.6 (2H, t, J = 6.7 Hz, CH2), 2.1 (2H, p, J = 3.9, 3.8 Hz, CH2), 1.9 (2H, s, NH2), 
1.6 (2H, p, J = 7.3, 6.5 Hz, CH2), 1.3–1.5 (4H, br, CH2); IR (film) ν (cm−1): 1567.9, 2856.5, 2931.8, 
3310.4; MS (FAB) m/z (M + 1) 270.3, 197.1, 185.0; MS-HR (FAB) Calc. for C17H23N3: 269.1892 
Found: 270.19712 (M + 1). 
3.1.8. N'-(2,3-Dihydro-1H-cyclopenta[b]quinolin-9-yl)hexane-1,6-diamine (4e) 
A mixture of 3 (0.71 g, 3.5 mmol), 1,6-diaminohexane (0.82 g, 7 mmol), phenol (1.5 g), and NaI 
(0.07 g) was combined as above to afford 4e as an oil. Compound 4e: yield 64%; 1H NMR (CD3OD) 
(δ ppm.): 8.0 (1H, d, J = 8.3 Hz, ArH), 7.7 (1H, d, J = 8.3 Hz, ArH), 7.5 (1H, t, J = 7.8 Hz, ArH),  
7.3 (1H, t, J = 7.8 Hz, ArH), 3.6 (2H, t, J = 7.1 Hz, NHCH2), 3.2 (2H, t, J = 7.1 Hz, CH2), 3.0 (4H, t,  
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J = 7.8 Hz, CH2NH2), 2.6 (2H, t, J = 6.8 Hz, CH2), 2.1 (2H, p, J = 7.6, 7.3 Hz, CH2), 1.6–1.7 (2H, m, 
CH2), 1.3–1.5 (6H, br, CH2); IR (film) ν (cm−1): 1567.5, 2855.0, 2928.4, 3350.4; MS (FAB)  
m/z (M + 1) 284.3, 197.0, 185.0; MS-HR (FAB) Calc. for C18H25N3: 283.2048 Found: 283.20426. 
3.1.9. N'-(2,3-Dihydro-1H-cyclopenta[b]quinolin-9-yl)heptane-1,7-diamine (4f) 
A mixture of 3 (0.75 g, 3.5 mmol), 1,7-diaminoheptane (0.92 g, 7 mmol), phenol (1.5 g), and NaI 
(0.07 g) was combined as above to afford 4f as an oil. Compound 4f: yield 72%; 1H NMR (CDCl3)  
(δ ppm.): 7.9 (1H, d, J = 7.5 Hz, ArH), 7.7 (1H, t, J = 8.3 Hz, ArH), 7.5 (1H, t, J = 7.1 Hz, ArH), 7.4 
(1H, t, J = 6.9 Hz, ArH), 4.6 (1H, s, NH), 3.6 (2H, m, NHCH2), 3.3 (2H, t, J = 7.5 Hz, CH2), 3.0 (2H, t, 
J = 7.7 Hz, CH2NH2), 2.6 (2H, t, J = 6.7 Hz, CH2), 2.1 (2H, p, J = 7.7, 7.3 Hz, CH2), 1.7 (2H, s, NH2), 
1.5–1.6 (2H, m, CH2CH2), 1.2–1.5 (8H, br, CH2CH2); IR (film) ν (cm−1): 1567.9, 2853.9, 2927.9, 
3294.4; MS (FAB) m/z (M + 1) 298.3, 197.0, 185.0; MS-HR (FAB) Calc. for C19H27N3: 297.2205 
Found: 298.22911 (M + 1). 
3.1.10. N'-(2,3-Dihydro-1H-cyclopenta[b]quinolin-9-yl)octane-1,8-diamine (4g) 
A mixture of 3 (0.71 g, 3.5 mmol), 1,8-diaminooctane (1.00 g, 7 mmol), phenol (1.5 g), and NaI 
(0.07 g) was combined as above to afford 4g as an oil. Compound 4g: yield 68%; 1H NMR (CDCl3)  
(δ ppm.): 7.8 (1H, d, J = 8.3 Hz, ArH), 7.5 (1H, t, J = 7.3 Hz, ArH), 7.3 (1H, t, J = 7.5 Hz, ArH), 4.5 
(1H, s, NH), 3.5 (2H, m, NHCH2), 3.1 (2H, t, J = 7.1 Hz, CH2), 3.0 (2H, d, J = 7.7 Hz, CH2NH2), 2.6 
(2H, t, J = 6.5 Hz, CH2), 1.5–1.6 (4H, br, CH2, NH2), 1.1–1.5 (10H, br, CH2); IR (film) ν (cm−1): 
1567.2, 2853.2, 2925.5, 3329.5; MS (FAB) m/z (M + 1) 312.5, 197.1, 185.1; MS-HR (FAB) Calcd. for 
C20H29N3: 311.2361 Found: 312.24442 (M + 1). 
3.1.11. N'-(2,3-Dihydro-1H-cyclopenta[b]quinolin-9-yl)nonane-1,9-diamine (4f) 
A mixture of 3 (0.71 g, 3.5 mmol), 1,9-diaminononane (1.10 g, 7 mmol), phenol (1.5 g), and NaI 
(0.07 g) was combined as above to afford 4f as an oil. Compound 4f: yield 66%; 1H NMR (CDCl3)  
(δ ppm.): 7.8 (1H, d, J = 7.3 Hz, ArH), 7.6 (1H, d, J = 7.5 Hz, ArH), 7.5 (1H, t, J = 6.9 Hz, ArH), 7.2 
(1H, t, J = 6.9 Hz, ArH), 4.6 (1H, s, NH), 3.5 (2H, m, NHCH2), 3.1 (2H, t, J = 7.1 Hz CH2), 3.0 (2H, t, 
J = 7.7 Hz, CH2NH2), 2.6 (2H, t, J = 6.9 Hz CH2), 2.1 (2H, p, J = 7.7, 7.7 Hz CH2), 1,7 (2H, s, NH2), 
1.5–1.6 (2H, m, CH2CH2), 1.1–1.3 (14H, br, CH2CH2); IR (film) ν (cm−1): 1568.0, 2852.5, 2925.7, 
3294.4; MS (FAB) m/z (M + 1) 326.3, 185.0; MS-HR (FAB) Calc. for C21H31N3: 325.2518 Found: 
326.26086 (M + 1). 
3.1.12. N-{5-[2-(2,3-Dihydro-1H-cyclopenta[b]quinolin-9-ylamino)ethylcarbamoyl]pyridin-2-yl} 
hydrazinecarboxylic Acid tert-Butyl Ester (5a) 
To the 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT) (1.76 g, 10 mmol) and 2 (2.53 g, 10 mmol) 
in THF (10 mL), N-methylmorpholine (1.1 mL, 10 mmol) was added drop by drop at a rate sufficient 
to keep the temperature between −5 °C and 0 °C. Stirring was continued at 0 °C for 1–4 h until all 
CDMT was consumed. Subsequently, to the crude mixture obtained as described above, 4a (2.27 g,  
10 mmol) in THF (8 mL) at −5 °C to 0 °C was added. Stirring was continued at 0 °C for 2 h, and then 
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for 12 h at room temperature. Precipitate formed and was isolated by filtration. Recrystallization  
from ethyl acetate afforded the desired product 5a as a yellow solid. Compound 5a: yield 68%; mp 
200–202 °C; 1H NMR (CD3OD) (δ ppm.): 8.5 (1H, s, ArH),8.3 (1H, d, J = 8.3 Hz, ArH), 7.9 (1H, d,  
J = 11.5 Hz, ArH), 7.8 (1H, t, J = 7.1 Hz, ArH), 7.7 (1H, d, J = 8.5 Hz, ArH), 7.6 (1H, t, J = 7.1 Hz, 
ArH), 6.7 (1H, d, J = 8.5 Hz, ArH), 4.0 (2H, t, J = 5.6 Hz, CH2), 3.7 (2H, t, J = 6.0 Hz, CH2), 3.4 (2H, 
t, J = 6.6 Hz, CH2), 3.1 (2H, t, J = 7.8 Hz, CH2), 2.3 (2H, p, J = 7.6, 7.8 Hz, CH2), 1.3–1.5 (9H, m, 
BOC); IR (KBr) ν (cm−1): 1464.2, 1610.9, 1740.6, 2869.2, 2936.2, 3422.1; MS (FAB) m/z (M + 1) 
463.4, 363.2; 183.1; MS-HR (FAB) Calc. for C25H30N6O3: 462.23794 Found: 463.24583 (M + 1). 
3.1.13. N-{5-[3-(2,3-Dihydro-1H-cyclopenta[b]quinolin-9-ylamino)propylcarbamoyl]pyridin-2-yl} 
hydrazinecarboxylic Acid tert-Butyl Ester (5b) 
A mixture of 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT) (1.76 g, 10 mmol), 2 (2.53 g, 10 mmol) 
in THF (10 mL), and N-methylmorpholine (1.1 mL, 10 mmol) and after 4 h 4b (2.41 g, 10 mmol) in 
THF were combined as above to afford 5b as yellow solid. Compound 5b: yield 66%; mp 159–161 °C; 
1H NMR (CD3OD) (δ ppm.): 8.5 (1H, s, ArH),8.3 (1H, d, J = 8.5 Hz, ArH), 7.9 (1H, d, J = 9.0 Hz, 
ArH), 7.8 (1H, t, J = 5.9 Hz, ArH), 7.7 (1H, d, J = 7.6 Hz, ArH), 7.6 (1H, t, J = 8.5 Hz, ArH), 6.7 (1H, 
d, J = 8.5 Hz, ArH), 3.8 (2H, t, J = 6.8 Hz, CH2), 3.7 (2H, t, J = 4.6 Hz, CH2), 3.5 (2H, t, J = 6.4 Hz, 
CH2), 3.3 (2H, m, NH), 3.1 (2H, t, J = 7.8 Hz, CH2), 2.5 (2H, m, NH), 2.2 (2H, p, J = 7.8, 7.6 Hz, 
CH2), 2.0 (2H, p, J = 7.6, 5.1 Hz, CH2), 1.3–1.5 (9H, m, BOC); IR (KBr) ν (cm−1): 1470.7, 1635.8, 
1721.1, 2853.4, 2967.2, 3259.6; MS (FAB) m/z (M + 1) 477.3, 377.3, 183.0; MS-HR (FAB) Calc. for 
C26H32N6O3: 476.25359 Found: 477.25943 (M + 1). 
3.1.14. N-{5-[4-(2,3-Dihydro-1H-cyclopenta[b]quinolin-9-ylamino)butylcarbamoyl]pyridin-2-yl} 
hydrazinecarboxylic Acid tert-Butyl Ester (5c) 
A mixture of 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT) (1.76 g, 10 mmol), 2 (2.53 g, 10 mmol) 
in THF (10 mL), and N-methylmorpholine (1.1 mL, 10 mmol) and after 4 h 4c (2.55 g, 10 mmol) in 
THF were combined as above to afford 5c as yellow solid. Compound 5c: yield 67%; mp 145–148 °C; 
1H NMR (CD3OD) (δ ppm.): 8.5 (1H, s, ArH),8.3 (1H, d, J = 7.9 Hz, ArH), 7.9 (1H, m, ArH), 7.8 (1H, 
t, J = 7.3 Hz, ArH), 7.7 (1H, d, J = 6.9 Hz, ArH), 7.6 (1H, t, J = 6.9 Hz, ArH), 6.7 (1H, d, J = 8.3 Hz, 
ArH), 3.8 (2H, t, J = 6.9 Hz, CH2), 3.7 (2H, t, J = 4.6 Hz, CH2), 3.3–3.4 (4H, m, NH, CH2), 3.1 (2H, t, 
J = 7.9 Hz, CH2), 2.5 (2H, m, NH), 2.3 (2H, p, J = 7.7, 9.3 Hz, CH2), 1.7 (4H, m, CH2), 1.3–1.5 (9H, 
m, BOC); IR (KBr) ν (cm−1): 1466.6, 1634.1, 1721.1, 2934.4, 3260.6; MS (FAB) m/z (M + 1) 491.3, 
391.3, 185.1; MS-HR (FAB) Calc. for C27H34N6O3: 490.26924 Found: 491.27811 (M + 1). 
3.1.15. N-{5-[5-(2,3-Dihydro-1H-cyclopenta[b]quinolin-9-ylamino)pentylcarbamoyl]pyridin-2-yl} 
hydrazinecarboxylic Acid tert-Butyl Ester (5d) 
A mixture of 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT) (1.76 g, 10 mmol), 2 (2.53 g, 10 mmol) 
in THF (10 mL), and N-methylmorpholine (1.1 mL, 10 mmol) and after 4 h 4d (2.69 g, 10 mmol) in 
THF were combined as above to afford 5d as yellow solid. Compound 5d: yield 70%; mp 106–108 °C; 
1H NMR (CD3OD) (δ ppm.): 8.4 (1H, s, ArH),8.2 (1H, d, J = 8.7 Hz, ArH), 7.9 (1H, d, J = 8.9 Hz, 
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ArH), 7.8 (1H, t, J = 5.6 Hz, ArH), 7.7 (1H, d, J = 8.1 Hz, ArH), 7.5 (1H, t, J = 8.3 Hz, ArH), 6.6 (1H, 
d, J = 8.9 Hz, ArH), 3.8 (2H, t, J = 6.9 Hz, CH2), 3.7 (2H, t, J = 4.8 Hz, CH2), 3.4 (2H, m, NH), 3.3 
(2H, t, J = 7.1 Hz, CH2), 3.1 (2H, t, J = 7.7 Hz, CH2), 2.5 (2H, m, NH), 2.2 (2H, p, J = 7.9, 7.5 Hz, 
CH2), 1.6–1.8 (6H, m, CH2), 1.3–1.5 (9H, m, BOC); IR (KBr) ν (cm−1): 1465.2, 1634.4, 1716.0, 
2855.0, 2927.0, 3275.6; MS (FAB) m/z (M + 1) 505.4, 405.3, 185.0; MS-HR (FAB) Calc. for 
C28H36N6O3: 504.28489 Found: 505.29257 (M + 1). 
3.1.16. N-{5-[6-(2,3-Dihydro-1H-cyclopenta[b]quinolin-9-ylamino)hexylcarbamoyl]pyridin-2-yl} 
hydrazinecarboxylic Acid tert-Butyl Ester (5e) 
A mixture of 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT) (1.76 g, 10 mmol), 2 (2.53 g, 10 mmol) 
in THF (10 mL), and N-methylmorpholine (1.1 mL, 10 mmol) and after 4 h 4c (2.83 g, 10 mmol) in 
THF were combined as above to afford 5c as yellow solid. Compound 5c: yield 75%; mp 110–112 °C; 
1H NMR (CD3OD) (δ ppm.): 8.5 (1H, s, ArH), 8.3 (1H, d, J = 8.1 Hz, ArH), 8.0 (1H, d, J = 9.1 Hz, 
ArH), 7.8 (1H, t, J = 5.7 Hz, ArH), 7.7 (1H, d, J = 7.5 Hz, ArH), 7.6 (1H, t, J = 7.1 Hz, ArH), 6.7 (1H, 
d, J = 8.9 Hz, ArH), 3.8 (2H, t, J = 7.2 Hz, CH2), 3.7 (2H, t, J = 4.8 Hz, CH2), 3.4 (4H, m, NH, CH2), 
3.2 (2H, t, J = 5.4 Hz, CH2), 2.5 (2H, m, NH), 2.3 (2H, p, J = 7.7, 7.7 Hz, CH2), 1.8 (4H, m, CH2), 1.7 
(4H, m, CH2), 1.3–1.5 (9H, m, BOC); IR (KBr) ν (cm−1): 1466.2, 1634.4, 1717.01, 2855.5, 2930.2, 
3250.3; MS (FAB) m/z (M + 1) 519.3, 419.3, 185.0; MS-HR (FAB) Calc. for C29H38N6O3: 518.30054 
Found: 519.30705 (M + 1). 
3.1.17. N-{5-[7-(2,3-Dihydro-1H-cyclopenta[b]quinolin-9-ylamino)heptylcarbamoyl]pyridin-2-yl} 
hydrazinecarboxylic Acid tert-Butyl Ester (5f) 
A mixture of 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT) (1.76 g, 10 mmol), 2 (2.53 g, 10 mmol) 
in THF (10 mL), and N-methylmorpholine (1.1 mL, 10 mmol) and after 4 h 4d (2.97 g, 10 mmol) in 
THF were combined as above to afford 5d as yellow solid. Compound 5d: yield 66%; mp 105–107 °C; 
1H NMR (CD3OD) (δ ppm.): 8.5 (1H, s, ArH), 8.3 (1H, d, J = 8.7 Hz, ArH), 8.0 (1H, d, J = 6.9 Hz, 
ArH), 7.8 (1H, t, J = 8.1 Hz, ArH), 7.7 (1H, d, J = 8.5 Hz, ArH), 7.6 (1H, t, J = 6.9 Hz, ArH), 6.7 (1H, 
d, J = 8.7 Hz, ArH), 4.0 (2H, t, J = 4.0 Hz, CH2), 3.8 (2H, t, J = 7.1 Hz, CH2), 3.4 (2H, t, J = 6.1 Hz, 
CH2), 3.2 (2H, t, J = 7.9 Hz, CH2), 2.3 (2H, p, J = 8.1, 6.9 Hz, CH2), 1.8 (4H, m, CH2), 1.6 (6H, m, 
CH2), 1.3–1.5 (9H, m, BOC); IR (KBr) ν (cm−1): 1566.5, 1717.7, 2855.1, 2927.2, 3295.0; MS  
(FAB) m/z (M + 1) 533.3, 433.3, 185.0; MS-HR (FAB) Calc. for C30H40N6O3: 532.31619 Found: 
533.32329 (M + 1). 
3.1.18. N-{5-[8-(2,3-Dihydro-1H-cyclopenta[b]quinolin-9-ylamino)octylcarbamoyl]pyridin-2-yl} 
hydrazinecarboxylic Acid tert-Butyl Ester (5g) 
A mixture of 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT) (1.76 g, 10 mmol), 2 (2.53 g, 10 mmol) 
in THF (10 mL), and N-methylmorpholine (1.1 mL, 10 mmol) and after 4 h 4c (3.11 g, 10 mmol) in 
THF were combined as above to afford 5c as yellow solid. Compound 5c: yield 46%; mp 134–136 °C; 
1H NMR (CD3OD) (δ ppm.): 8.5 (1H, s, ArH), 8.3 (1H, d, J = 8.7 Hz, ArH), 8.0 (1H, d, J = 6.6 Hz, 
ArH), 7.8 (1H, t, J = 6.9 Hz, ArH), 7.7 (1H, d, J = 8.5 Hz, ArH), 7.6 (1H, t, J = 6.9 Hz, ArH), 6.7 (1H, 
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d, J = 8.7 Hz, ArH), 4.6 (2H, m, NH), 4.0 (2H, t, J = 3.8 Hz, CH2), 3.8 (2H, t, J = 7.3 Hz, CH2), 3.4 
(4H, m, NH,CH2), 3.2 (2H, t, J = 7.9 Hz, CH2), 2.3 (2H, p, J = 7.7, 6.9 Hz, CH2), 1.7 (6H, m, CH2), 1.6 
(6H, m, CH2), 1.3–1.5 (9H, m, BOC); IR (KBr) ν (cm−1): 1466.7, 1634.1, 1717.2, 2854.3, 2928.2, 
3259.6; MS (FAB) m/z (M + 1) 547.3, 447.3, 183.0; MS-HR (FAB) Calc. for C31H42N6O3: 546.33184 
Found: 547.33977 (M + 1). 
3.1.19. N-{5-[9-(2,3-Dihydro-1H-cyclopenta[b]quinolin-9-ylamino)nonylcarbamoyl]pyridin-2-yl} 
hydrazinecarboxylic Acid tert-Butyl Ester (5h) 
A mixture of 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT) (1.76 g, 10 mmol), 2 (2.53 g, 10 mmol) 
in THF (10 mL), and N-methylmorpholine (1.1 mL, 10 mmol) and after 4 h 4d (3.26 g, 10 mmol) in 
THF were combined as above to afford 5d as yellow solid. Compound 5d: yield 62%; mp 81–83 °C; 
1H NMR (CD3OD) (δ ppm.): 8.5 (1H, s, ArH), 8.4 (1H, d, J = 8.3 Hz, ArH), 8.0 (1H, m, ArH), 7.8 
(1H, t, J = 8.3 Hz, ArH), 7.7 (1H, d, J = 8.1 Hz, ArH), 7.5 (1H, t, J = 7.3 Hz, ArH), 6.6 (1H, d, J = 9.1 Hz, 
ArH), 4.6 (2H, m, NH), 4.0 (2H, m, CH2), 3.8 (2H, m, CH2), 3.4 (2H, m, NH), 3.0 (2H, m, CH2), 2.7 
(2H, m, CH2), 2.0 (2H, p, J = 7.7, 6.9 Hz, CH2), 1.8 (6H, m, CH2), 1.7 (8H, m, CH2), 1.3–1.5 (9H, m, 
BOC); IR (KBr) ν (cm−1): 1489.8, 1636.3, 1709.1, 2868.7, 2927.8, 3421.7; MS (FAB) m/z (M + 1) 
561.5, 461.3, 183.0; MS-HR (FAB) Calc. for C32H44N6O3: 560.34749 Found: 561.35526 (M + 1). 
3.1.20. 6-Hydrazino-N-[2-(2,3-dihydro-1H-cyclopenta[b]quinolin-9-ylamino)Ethyl]nicotinamide 
hydrochloride (6a) 
Compound 5a (0.20 g, 0.43 mmol) was dissolved in ether (2 mL), HCl/ether (4 mL) was added, and 
the reaction mixture was stirred at room temperature. After 24 h, the solution became cloudy and 
precipitate formed. The precipitate was isolated by filtration and the solid was washed with ether and 
dried. Compound 6a: yield 34%; mp 235–136 °C; 1H NMR (CD3OD) (δ ppm.): 8.5 (1H, s, ArH), 8.4 
(1H, d, J = 8.3 Hz, ArH), 8.2 (1H, d, J = 9.0 Hz, ArH), 7.9 (1H, t, J = 7.6 Hz, ArH), 7.7 (1H, d, J = 8.3 Hz, 
ArH), 7.6 (1H, t, J = 8.1 Hz, ArH), 7.0 (1H, d, J = 9.0 Hz, ArH), 4.0 (2H, t, J = 5.9 Hz, CH2), 3.8 (2H, 
t, J = 5.9 Hz, CH2), 3.5 (2H, t, J = 7.1 Hz, CH2), 3.1 (2H, t, J = 7.8 Hz, CH2), 2.3 (2H, p, J = 7.6,  
7.6 Hz, CH2), IR (KBr) ν (cm−1): 1585.7, 1646.1, 2852.8, 2928.0, 3435.6; MS (FAB) m/z (M + 1) 
363.2, 348.2; 185.0; MS-HR (FAB) Calc. for C20H22N6O: 362.18551 Found: 363.19414 (M + 1). 
3.1.21. 6-Hydrazino-N-[3-(2,3-dihydro-1H-cyclopenta[b]quinolin-9-ylamino)propyl]nicotinamide 
hydrochloride (6b) 
A 5b (0.20 g, 0.42 mmol) were combined as above to afford 6b as brown solid. Compound 6b: 
yield 36%; mp 226–229 °C; 1H NMR (DMSO) (δ ppm.): 14.1 (1H, s, HCl), 9.9 (1H, s, NH), 8.9  
(1H, m, ArH), 8.8 (1H, m, ArH), 8.5 (1H, d, J = 8.7 Hz, ArH), 8.1 (1H, d, J = 8.9 Hz, ArH), 7.8 (1H, t, 
J = 7.3 Hz, ArH), 7.6 (1H, t, J = 7.7 Hz, ArH), 6.9 (1H, d, J = 8.5 Hz, ArH), 3.7 (4H, m, NH), 3.4–3.6 
(4H, m, CH2), 3.3 (2H, t, J = 6.9 Hz, CH2), 3.1 (2H, t, J = 8.3 Hz, CH2), 2.1 (2H, m, Hz, CH2), 1.9 
(2H, m, CH2); IR (KBr) ν (cm−1): 1585.3, 1648.5, 2857.0, 2933.0, 3277.6; MS (FAB) m/z (M + 1) 
377.2, 362.1; 185.0 MS-HR (FAB) Calc. for C21H24N6O: 376.20116 Found: 377.21072 (M + 1). 





A 5c (0.20 g, 0.41 mmol) were combined as above to afford 6c as yellow solid. Compound 6c: yield 
30%; mp 171–173 °C; 1H NMR (DMSO) (δ ppm.):14.3 (1H, s, HCl), 9.9 (1H, s, NH), 8.8 (1H, m, 
ArH), 8.7 (1H, m, ArH), 8.6 (1H, m, ArH), 8.1 (1H, d, J = 8.9 Hz, ArH), 7.8 (1H, t, J = 8.3 Hz, ArH), 
7.6 (1H, t, J = 6.7 Hz, ArH), 6.9 (1H, d, J = 8.5 Hz, ArH), 3.7 (4H, m, NH), 3.3–3.4 (4H, m, CH2), 3.2 
(2H, t, J = 7.7 Hz, CH2), 3.1 (2H, t, J = 7.7 Hz, CH2), 2.1 (2H, m, CH2), 1.6–1.8 (4H, m, CH2); IR 
(KBr) ν (cm−1): 1541.7, 1647.7, 2857.4, 2904.7, 3414.7; MS (FAB) m/z (M + 1) 391.4, 376.4, 185.0; 
MS-HR (FAB) Calc. for C22H26N6O: 391.21681 Found: 391.22435 (M + 1). 
3.1.23. 6-Hydrazino-N-[5-(2,3-dihydro-1H-cyclopenta[b]quinolin-9-ylamino)pentyl]nicotinamide 
hydrochloride (6d) 
A 5d (0.20 g, 0.40 mmol) were combined as above to afford 6d as brown solid. Compound 6d: 
yield 36%; mp 107–108 °C; 1H NMR (DMSO) (δ ppm.):14.4 (1H, s, HCl), 10.0 (1H, s, NH), 8.9  
(1H, m, ArH), 8.8 (2H, m, ArH), 8.1 (1H, d, J = 8.9 Hz, ArH), 7.8 (1H, t, J = 10.1 Hz, ArH), 7.6 (1H, 
t, J = 7.5 Hz, ArH), 6.9 (1H, d, J = 8.9 Hz, ArH), 3.7 (4H, m, NH), 3.3 -3.4 (4H, m, CH2), 3.2 (2H, t,  
J = 9.9 Hz, CH2), 3.1 (2H, t, J = 7.5 Hz, CH2), 2.1 (2H, p, J = 7.5, 7.1 Hz, CH2), 1.4–1.6 (6H, m, CH2); 
IR (KBr) ν (cm−1): 1558.4, 1647.7, 2858.4, 2931.2, 3385.2; MS (FAB) m/z (M + 1) 405.3, 390.3, 
185.0; MS-HR (FAB) Calc. for C23H28N6O: 404.23246 Found: 405.24165 (M + 1). 
3.1.24. 6-Hydrazino-N-[6-(2,3-dihydro-1H-cyclopenta[b]quinolin-9-ylamino)hexyl]nicotinamide 
hydrochloride (6e) 
A 5e (0.20 g, 0.39 mmol) were combined as above to afford 6e as yellow solid. Compound 6e: yield 
33%; mp 166–167 °C; 1H NMR (DMSO) (δ ppm.):14.4 (1H, s, HCl), 10.0 (1H, s, NH), 8.9 (1H, m, 
ArH), 8.8 (2H, m, ArH), 8.1 (1H, d, J = 6.7 Hz, ArH), 7.9 (1H, t, J = 8.1 Hz, ArH), 7.6 (1H, t,  
J = 8.1 Hz, ArH), 6.9 (1H, d, J = 8.9 Hz, ArH), 3.7 (4H, m, NH), 3.4–3.5 (4H, m, CH2), 3.3 (2H, t,  
J = 7.1 Hz, CH2), 3.1 (2H, t, J = 7.7 Hz, CH2), 2.2 (2H, p, J = 7.7, 7.1 Hz, CH2), 1.4–1.7 (8H, m, CH2); 
IR (KBr) ν (cm−1): 1559.3, 1636.9, 2857.4, 2930.2, 3424.8; MS (FAB) m/z (M + 1) 419.3, 404.3, 
185.0; MS-HR (FAB) Calc. for C24H30N6O: 418.24811 Found: 419.25754 (M + 1). 
3.1.25. 6-Hydrazino-N-[7-(2,3-dihydro-1H-cyclopenta[b]quinolin-9-ylamino)heptyl]nicotinamide 
hydrochloride (6f) 
A 5f (0.20 g, 0.38 mmol) were combined as above to afford 6f as brown solid. Compound 6f: yield 
43%; mp 105–107 °C; 1H NMR (DMSO) (δ ppm.):14.4 (1H, s, HCl), 10.0 (1H, s, NH), 8.8 (1H, m, 
ArH), 8.6 (2H, m, ArH), 8.1 (1H, d, J = 6.5 Hz, ArH), 7.9 (1H, t, J = 9.5 Hz, ArH), 7.6 (1H, t,  
J = 6.7 Hz, ArH), 6.9 (1H, d, J = 8.9 Hz, ArH), 3.7 (4H, m, NH), 3.4 (4H, m, CH2), 3.2 (2H, t, J = 7.5 Hz, 
CH2), 3.1 (2H, t, J = 7.7 Hz, CH2), 2.2 (2H, p, J = 7.1, 7.1 Hz, CH2), 1.3–1.7 (10H, m, CH2); IR (KBr) 
ν (cm−1): 1558.9, 1648.0, 2855.3, 2926.6, 3259.7, 3405.0; MS (FAB) m/z (M + 1) 433.3, 418.3, 185.0; 
MS-HR (FAB) Calc. for C25H32N6O: 432.26376 Found: 433.27207 (M + 1). 





A 5g (0.20 g, 0.37 mmol) were combined as above to afford 6g as yellow solid. Compound 6g: 
yield 43%; mp 170–173 °C; 1H NMR (DMSO) (δ ppm.):14.2 (1H, s, HCl), 9.9 (1H, s, NH), 8.8 (1H, 
m, ArH), 8.6 (2H, m, ArH), 8.1 (1H, d, J = 8.9 Hz, ArH), 7.8 (1H, m, ArH), 7.6 (1H, m, ArH), 6.9 
(1H, d, J = 8.3 Hz, ArH), 3.7 (4H, m, NH), 3.3 (4H, m, CH2), 3.2 (2H, t, J = 5.7 Hz, CH2), 3.1 (2H, t,  
J = 9.1 Hz, CH2), 2.2 (2H, p, J = 7.3, 7.3 Hz, CH2), 1.3–1.8 (12H, m, CH2); IR (KBr) ν (cm−1): 1558.5, 
1634.0, 2854.2, 2926.7, 3200.6, 3422.2; MS (FAB) m/z (M + 1) 447.1, 432.2, 185.0; MS-HR (FAB) 
Calc. for C26H34N6O: 446.27941 Found: 447.28878 (M + 1). 
3.1.27. 6-Hydrazino-N-[9-(2,3-dihydro-1H-cyclopenta[b]quinolin-9-ylamino)nonyl]nicotinamide 
hydrochloride (6h) 
A 5h (0.20 g, 0.35 mmol) were combined as above to afford 6h as brown solid. Compound 6h: 
yield 44%; mp 85–87 °C; 1H NMR (DMSO) (δ ppm.):14.5 (1H, s, HCl), 10.0 (1H, s, NH), 8.9 (1H, m, 
ArH), 8.8 (2H, m, ArH), 8.1 (1H, d, J = 6.9 Hz, ArH), 7.8 (1H, t, J = 6.7 Hz, ArH), 7.6 (1H, t,  
J = 7.1 Hz, ArH), 6.9 (1H, d, J = 8.9 Hz, ArH), 3.7 (4H, m, NH), 3.4 (4H, m, CH2), 3.3 (2H, m, CH2), 
3.2 (2H, t, J = 7.7 Hz, CH2), 2.1 (2H, m, CH2), 1.5–1.7 (14H, m, CH2); IR (KBr) ν (cm−1): 1585.8, 
1647.3, 2853.5, 2925.4, 3438.1; MS (FAB) m/z (M + 1) 461.3, 446.3, 183.0; MS-HR (FAB) Calc. for 
C27H36N6O: 460.29506 Found: 461.30121 (M + 1). 
3.2. Biochemical Studies 
Determination of the inhibitory activity of all synthesized compounds towards AChE and BChE 
was performed by means of Ellman’s spectrophotometric  method with our own modifications. Every 
sample contained 5,5'-dithiobisnitrobenzoic acid (DTNB, 0.05 mL, 0.5 M), acetylthiocholine iodide 
(substrate), newly synthesized inhibitor, and AChE (5 units/mL) or BChE (5 units/mL), respectively, 
in cholinesterases activity measurements. Every measurement was conducted in the presence of 
phosphate buffer (0.1 M, pH 8.0) at 37 °C. The total volume of every sample amounted to 3 mL. 
Measurement procedure was identical for all samples. All ingredients were incubated for 1 min and 
then the absorbance was recorded at 412 nm. Seven concentrations of acetylthiocholine iodide were 
used in order to obtain the inhibition curves for every compound. Every measurement was conducted 
three times. Also, samples without inhibitor were evaluated in order to obtain absolute AChE and 
BChE activity. The value of IC50, defined as the drug concentration that contributes to the inhibition of 
50% AChE or BChE activity, was determined by non-linear and linear regression. 
All reagents: DTNB, enzymes (C2629 Acetylcholinesterase from Electrophorus electricus (electric 
eel) and C4290 Butyrylcholinesterase from equine serum) and acetylthiocholine iodide were purchased 
from Sigma-Aldrich. 
3.3. Molecular Modeling 
The three-dimensional structures of inhibitors were created by Corina on-line (Molecular Networks) 
and subsequently prepared with Sybyl 8.0 (Tripos). Atom types were checked, hydrogen atoms were 
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added, and, then, Gasteiger-Marsili charges were assigned. Ligands were bound to acetylcholinesterase 
from 2CKM and butyrylcholinesterase from 1P0I crystal complex. Protein was prepared before 
binding with GoldSuite 5.0.1 (CCDC). All histidine residues were protonated at Nε, the hydrogen 
atoms were added, ligand and water molecules were removed, and the binding site was defined as all 
amino acid residues within 10 Å from bis-(7)-tacrine for AChE and 20 Å from the glycerol molecule 
present in the active center of BChE. A standard set of genetic algorithms with population size of 100, 
number of operations 100,000, and clustering with a tolerance of 1Å was applied. As a result 10 ligand 
poses, sorted by GoldScore (AChE) and ChemScore (BChE) function value were obtained. The results 
were visualized by PyMOL 0.99rc6 (DeLano Scientific LLC). 
3.4. Spectrophotometric Experiments 
The absorption spectrum was obtained by scanning the sample between 200 and 350 nm with a 
Perkin Elmer spectrophotometer. The experiment was started with a solution of pure water at room 
temperature. The stability of compound 6a was assessed by monitoring the variability of the spectrum 
at regular intervals (15 min) over 4 h. 
3.5. Radiolabelling 
For radiolabeling with Tc-99m, 1 mg of the ligand 6a was dissolved in 150 µL of water. 
Subsequently, 100 mg of tricine and 1.5 mL of technetium eluate were added together with 25 µL of 
SnCl2 in ethanol (1 mg/mL). After 30 min incubation at room temperature, quality control was 
performed by HPLC analysis. HPLC analysis was performed on an Agilent System 1100 Series with 
UV and radiometric detection, with LiChrocart column 250-3 Luichrospher 100 RP-18 (5 µm). Flow 
rate was 1 mL/min. 
Gradient I: 
Mobile phase A: 0.9% NaCl, B: CH3CN. 
1–25 min 50% B. 
25–30 min 50%–100% B. 
30–35 min 100% B. 
35–40 min 100%–0% B. 
Gradient II:  
0–10 min 0% B. 
10–25 min 0%–100% B. 
25–30 min 100% B. 
30–35 min 100%–0% B. 
3.6. Biodistribution Studies in Rats 
3.6.1. Animals 
For biological experiments, the radiolabelled compound was dissolved in saline to a concentration 
of the ligand equal to 100 µg/mL. Intravenous dose was 20 µg per animal  
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For biodistribution studies, male Wistar rats weighing 190–260 g were used. Prior to the 
experiment, the animals were fasted overnight (to empty the bowels), but had free access to water. All 
animal experiments were approved by the Ethics Committee of the Faculty of Pharmacy, Charles 
University, Hradec Kralove. 
3.6.2. Biodistribution in Rats 
The agent was administered to rats intravenously in a volume of 0.2 mL. During the course of the 
experiments, each animal was placed in an individual cage. At various time points after injection, the 
carotid artery was exposed under ether anesthesia and a blood sample was collected in glass tubes 
containing dry heparin. The rats were sacrificed and dissected. The organs of interest were weighed 
and counted for radioactivity in an automatic gamma counter (1480 Wizard 3). 
The results were expressed as mean ± standard deviations of at least four animals.  
4. Conclusions  
As a consequence of a limited number of efficacious drugs in the treatment of AD, many scientific 
teams are aiming to discover novel compounds able to improve cholinergic neurotransmission. 
Currently approved AChE inhibitors, such as galantamine, rivastigmine, and donepezil, provide 
comparatively little chance for a prolonged improvement in cognitive functions. Thus, the search for 
novel compounds with anticholinesterase activity continues as numerous scientists are focused on the 
development of novel compounds such as cystamine-tacrine dimers [37], bisquaternary isoquinolinium 
derivatives [38], diversely substituted furo[2,3-b]quinolin-4-amine and pyrrolo[2,3-b]quinolin-4-amine 
derivatives [39], and tacrine-8-hydroxyquinoline hybrid [40] that might increase the level of ACh. 
Several teams have also utilized derivatives of tacrine as potential radiopharmaceuticals. Tacrine 
and its modified structure derivatives were marked with radioactive isotope in order to determine the 
level of AChE or BChE as a function of tacrine analogue labeled isotope accumulated in the target  
site [41,42]. Also, other AChE inhibitors such as donepezil and huperzine were modified and marked 
with radioisotopes [43,44]. 
In our previous papers, we presented the synthesis and biological evaluation of derivatives of 
tetrahydroacridine derivatives with hydrazine nicotinate (HYNIC) moiety [45,46]. The fragment of 
tetrahydroacridine that possesses the possibility to inhibit both the moieties of cholinesterase and 
HYNIC has the potential to be utilized as a co-ligand for radiolabeling.  
As described in this article, eight synthesized compounds differed from each other only in the 
length of the aliphatic chain between the tetrahydroacridine and the hydrazine nicotinate moiety. 
According to the results of the studies, compounds showing the highest activity with regard to AChE 
inhibition were those with six and eight carbon atoms in the aliphatic chain; which were approximately 
7- and 9- fold more active than tacrine, respectively. This data suggests that altering the molecule by 
incorporating a longer aliphatic chain proved to be a good choice. All novel compounds, apart from the 
one with six carbon atoms in the aliphatic chain, described in these studies were characterized, in 
comparison to tacrine, by lower inhibitory activity towards BChE [45,46]. 
Within this work, compared to our previous studies, the six membered ring of tetrahydroacridine 
was exchanged with a five membered ring; this influenced the activity and interaction with active sites. 
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Of all the synthesized compounds, the most active was 6h (IC50 = 3.65 nM). This compound was about 
1.5-fold more active than tacrine and, as compared to this reference compound, more selective towards 
AChE. Compound 6g exhibited a similar value of IC50 to that of tacrine. Similarly to our previous 
studies, obtained data suggests that the activity of the synthesized compounds increases  
simultaneously with the length of the aliphatic chain between the hydrazine nicotinate moiety and  
2,3-dihydro-1H-cyclopenta[b]quinolone. Our data showed that all synthesized molecules were 
characterized by lower BChE inhibitory activity in comparison to tacrine. 
On the other hand, selectivity of the obtained compounds is very promising because the moiety of 
6-hydrazinenicotinic acid (HYNIC) is thought to be responsible for the binding of technetium-99m 
radiotracer (99mTc) (as reported previously by Abrams et al.) [26]. 
According to molecular modeling studies, all ligands were extended along the active gorge and 
interacted with both the catalytic and peripheral site of AChE. This dual type of binding to AChE is 
responsible for an additional function related to the interaction with β-amyloid. The mode of binding 
with BChE was similar; the main difference was the location of the hydrazinenicotinic fragment in the 
reduced peripheral anionic site of BChE. These results are of vital importance as it has been 
established that AChE not only plays a crucial role in cholinergic dysfunction, but also is involved in 
the β-amyloid cascade via the AChE peripheral anionic site (PAS), such as mediating the adhesion, 
differentiation and deposition of β-amyloid in AD. It has been reported that AChE is a protein 
associated with the amyloid core of mature senile plaques, pre-amyloid diffuse deposits, and cerebral 
blood vessels in AD brain. Alvares et al., in in vitro studies showed that AChE is incorporated into  
β-amyloid aggregates by forming macromolecular complexes with the growing β-amyloid fibrils. The 
following scientific work of Alvares demonstrated that these complexes accelerate the maturation of  
β-amyloid plaques and are more toxic at the cellular level than the amyloid fibrils alone [47,48]. 
Molecular modeling studies presented within this work revealed that synthesized compounds are dual 
binding site inhibitors; thus, there is a possibility to influence non-cholinergic functions of AChE 
including AChE-induced aggregation of β-amyloid. 
Biodistribution studies in rats revealed that compound 6a exhibited comparatively rapid blood 
radioactivity clearance. 99mTc-radioactivity was mainly located in the liver, and to a lesser extent in the 
kidney, lung, and the gastrointestinal tract. Low radioactivity concentrations in the brain suggest that 
these agents do not cross the blood-brain barrier, and, therefore, cannot be regarded as potential agents 
for diagnosis of Alzheimer’s disease. However, similarly to [11C]choline, the synthesized compounds 
might be further evaluated as molecules suitable for the detection of cancers in certain organs (e.g., 
liver, kidney, lungs) or to monitor the response to various therapies. For example, there are scientific 
reports which prove that [11C]choline, developed by Hara et al., as an oncologic PET (positron 
emission tomography) radiopharmaceutical, might be utilized with good results in the diagnosis of 
lung cancer [49], colon cancer [50], or prostate cancer [51]. Furthermore, [11C]choline and 
multimodality fusion imaging with integrated PET and contrast-enhanced CT (PET/CT) could be used 
to monitor the response to anti-androgenic therapy [52]. 
Results of our synthesis and analysis suggest that the obtained hybrids of  
2,3-dihydro-1H-cyclopenta[b]quinolone and 6-hydrazinonicotynic acid may be considered as novel 
potential anti-Alzheimer’s drugs. Conversely, these compounds, following radiolabeling, could be 
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used in the detection of the cholinergic deficit occurring in the peripheral nervous system or in the 
diagnosis of various types of cancers or to correct physiological functions.  
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